Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report.
Dong W, Dai A, Wu Z, Wang J, Wu T, Du Y, Tian W, Zheng J, Zhang Y, Wang H, Cai J, Dong S, Zhou Y, Li S, Xiao Z.
Dong W, et al. Among authors: du y.
Front Immunol. 2024 May 31;15:1371379. doi: 10.3389/fimmu.2024.1371379. eCollection 2024.
Front Immunol. 2024.
PMID: 38881888
Free PMC article.